中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

64 records (took 0.032 seconds)

    dapE GENE OF HELICOBACTER PYLORI AND dapE- MUTANT STRAINS OF HELICOBACTER PYLORI
    2.
    发明申请
    dapE GENE OF HELICOBACTER PYLORI AND dapE- MUTANT STRAINS OF HELICOBACTER PYLORI 审中-公开
    HELICOBACTER PYLORI的dapE基因和HELICOBACTER PYLORI的dapE < - >突变菌株

    公开(公告)号：WO1998027819A1

    公开(公告)日：1998-07-02

    申请号：PCT/US1997024147

    申请日：1997-12-23

    Applicant: VANDERBILT UNIVERSITY ,  BLASER, Martin, J. ,  KARITA, Mikio

    Inventor： VANDERBILT UNIVERSITY

    IPC: A01N63/00

    CPC classification number: A61K48/00 ,  A61K39/00 ,  A61K2039/51 ,  C12N1/20 ,  C12N9/80 ,  C12N15/74 ,  Y02A50/476

    Abstract: The invention provides the dapE gene of Helicobacter pylori and H. pylori dapE?-? mutants and to methods of using the mutants to express foreign genes and immunize against foreign agents. The dapE gene can consist of the nucleotide sequence defined in SEQ ID NO:1. Nucleic acids of the gidA gene and ORF2 or H. pylori are provided. Examples of these nucleic acids can be found in SEQ ID NO:3 and SEQ ID NO:5, respectively. Having provided these nucleic acids, hybridizing nucleic acids in accord with the description of hybridizing nucleic acids of dapE are also provided.

    Abstract translation: 本发明提供幽门螺旋杆菌和幽门螺杆菌dapEα- 突变体以及使用突变体表达外源基因并免疫外源药物的方法。 dapE基因可以由SEQ ID NO：1中定义的核苷酸序列组成。 提供了gidA基因和ORF2或幽门螺杆菌的核酸。 这些核酸的实例可以分别在SEQ ID NO：3和SEQ ID NO：5中找到。 提供了这些核酸，还提供了符合dapE杂交核酸描述的核酸杂交。

    GENETICALLY ENGINEERED YEAST WITH MODIFIED SIGNAL PEPTIDASE COMPLEX
    4.
    发明申请
    GENETICALLY ENGINEERED YEAST WITH MODIFIED SIGNAL PEPTIDASE COMPLEX 审中-公开
    具有修饰信号肽复合物的遗传工程YEAST

    公开(公告)号：WO1998013473A1

    公开(公告)日：1998-04-02

    申请号：PCT/US1997017597

    申请日：1997-09-25

    Applicant: VANDERBILT UNIVERSITY ,  FANG, Hong ,  GREEN, Neil ,  VAN KAER, Luc

    Inventor： VANDERBILT UNIVERSITY

    IPC: C12N01/15

    CPC classification number: C12N9/52 ,  C12N15/81

    Abstract: The present invention provides a yeast cell comprising a nucleic acid functionally encoding a eukaryotic (e.g., mammalian) protein homologue of a subunit (Sec11p, Spc1p, Spc2p and/or Spc3p) of the yeast signal peptidase complex. The yeast cell of this invention can be, for example, of the genus Saccharomyces, Schizosaccharomyces, Pichia, Hansenula, Kluyveromyces and/or Yarrowia. Furthermore, the yeast cell can lack one or more functional subunits (Sec11p, Spc1p, Spc2p and/or Spc3p) of the yeast signal peptidase complex. The present invention further provides a method for producing a protein heterologous to a yeast cell comprising expressing, in the yeast cell of this invention, a nucleic acid functionally encoding the heterologous protein under conditions which permit the expression of the nucleic acid as a precursor protein having a signal peptide and processing of the precursor protein to a signal peptide-cleaved form of the protein. A method is also provided for obtaining increased production of a protein heterologous to a yeast cell comprising expressing, in the yeast cell of this invention, a nucleic acid functionally encoding the heterologous protein under conditions which permit the expression of the nucleic acid as a precursor protein having a signal peptide and processing of the precursor protein to a signal peptide-cleaved form of the protein. Additionally provided is a method for producing a yeast cell capable of increased production of a protein heterologous to the yeast cell, comprising introducing into the yeast cell (with or without one or more functional SPC subunits) a nucleic acid which functionally encodes one or more eukaryotic protein homologues of the signal peptidase complex under conditions permitting the expression of the nucleic acid as the protein homologues.

    Abstract translation: 本发明提供了酵母细胞，其包含功能性编码酵母信号肽酶复合物的亚基（Sec11p，Spc1p，Spc2p和/或Spc3p）的真核（例如哺乳动物）蛋白质同源物的核酸。 本发明的酵母细胞可以是例如酵母属，裂殖酵母属，毕赤酵母，汉逊酵母，克鲁维酵母属和/或耶氏酵母属。 此外，酵母细胞可以缺乏酵母信号肽酶复合物的一个或多个功能性亚基（Sec11p，Spc1p，Spc2p和/或Spc3p）。 本发明还提供了一种用于生产与酵母细胞异源的蛋白质的方法，包括在本发明的酵母细胞中表达在允许表达核酸作为前体蛋白的条件下功能性编码异源蛋白质的核酸， 信号肽和前体蛋白与信号肽切割形式的蛋白质的加工。 还提供了用于获得增加对酵母细胞异源的蛋白质产生的方法，包括在本发明的酵母细胞中表达在允许核酸作为前体蛋白表达的条件下功能编码异源蛋白质的核酸 具有信号肽和将前体蛋白加工成信号肽切割形式的蛋白质。 另外提供了一种用于生产能够增加与酵母细胞异源的蛋白质产生的酵母细胞的方法，包括向功能上编码一种或多种真核生物的核酸引入酵母细胞（具有或不具有一个或多个功能性SPC亚基） 在允许核酸作为蛋白质同系物表达的条件下，信号肽酶复合物的蛋白质同系物。

    COMPOSITIONS OF ANTICHLAMYDIAL AGENTS FOR THE DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY CHLAMYDIA
    5.
    发明申请
    COMPOSITIONS OF ANTICHLAMYDIAL AGENTS FOR THE DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY CHLAMYDIA 审中-公开
    用于诊断和管理由CHLAMYDIA引起的感染的抗病毒药物的组合物

    公开(公告)号：WO1998006435A2

    公开(公告)日：1998-02-19

    申请号：PCT/US1997014402

    申请日：1997-08-14

    Applicant: VANDERBILT UNIVERSITY ,  MITCHELL, William, M. ,  STRATTON, Charles, W.

    Inventor： VANDERBILT UNIVERSITY

    IPC: A61K45/06

    CPC classification number: A61K31/455 ,  A61K45/06 ,  C07K14/295 ,  A61K2300/00

    Abstract: The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.

    Abstract translation: 本发明提供了一种用于诊断和管理衣原体物种，特别是肺炎衣原体感染的独特方法。 本发明部分地基于发现指向衣原体生命周期的各个阶段的药剂的组合在基本上减少感染方面是有效的。 还描述了包含抗结衣剂，新组合物和药物包装的组合的产品。

    COMPOSITIONS, KITS, AND METHODS FOR ADMINISTRATION OF ANTILIPEMIC AND ANTI-PLATELET AGGREGATION DRUGS
    8.
    发明申请
    COMPOSITIONS, KITS, AND METHODS FOR ADMINISTRATION OF ANTILIPEMIC AND ANTI-PLATELET AGGREGATION DRUGS 审中-公开
    组合物，试剂盒和方法，用于管理抗血小板聚集药物

    公开(公告)号：WO1996032942A1

    公开(公告)日：1996-10-24

    申请号：PCT/US1996005398

    申请日：1996-04-19

    Applicant: VITAL THERAPEUTICS, L.L.C. ,  VANDERBILT UNIVERSITY ,  KUHRTS, Eric, H. ,  ROBERTS, L., Jackson, II ,  MORROW, Jason, D.

    Inventor： VITAL THERAPEUTICS, L.L.C. ,  VANDERBILT UNIVERSITY

    IPC: A61K31/44

    CPC classification number: A61K31/60 ,  A61K31/455 ,  A61K31/54 ,  A61K31/621 ,  Y10S514/823 ,  A61K31/415 ,  A61K31/405 ,  A61K31/40 ,  A61K31/195 ,  A61K31/19 ,  A61K2300/00

    Abstract: The present invention concerns composition, kits and methods for reducing the flushing effect (cutaneous erythema) of an antilipemic drug, for treating hyperlipemia, for improving the effectiveness of an anti-platelet aggregating drug (e.g., in nonresponders) and for treating thrombosis. The present compositions and kits for reducing the flushing effect and for treating hyperlipemia contain an antilipemic drug such as niacin and either a sustained-release NSAID (such as aspirin) or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug. The kits contain (a) predosages of the NSAID and optional carboxylic acid compound and (b) an antilipemic dosage of the antilipemic drug, which optionally may be combined with NSAID and optional carboxylic acid compound in an amount effective to maintain the reduction of the flushing effect. The present method of treating hyperlipemia comprises predosing the patient with a sustained-release NSAID or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug at least 2 hours before administering the antilipemic drug. The present compositions and kits for increasing the effectiveness of an antiplatelet aggregating drug contain an NSAID such as aspirin, niacin or a congener thereof, and optionally, a carboxylic acid other than the NSAID niacin, such as citric acid.

    Abstract translation: 本发明涉及用于降低抗血脂药物的冲洗作用（皮肤红斑），用于治疗高脂血症，改善抗血小板聚集药物（例如，无应答者）的有效性和用于治疗血栓形成的组合物，试剂盒和方法。 用于降低冲洗效果和用于治疗高脂血症的本发明组合物和试剂盒含有抗血药物如烟酸和缓释NSAID（例如阿司匹林）或NSAID和除NSAID和抗脂药物之外的羧酸化合物。 试剂盒包含（a）NSAID和任选的羧酸化合物的预处理和（b）抗脂药物的抗脂肪剂量，其任选地可以与NSAID和任选的羧酸化合物组合，其量有效地保持冲洗的减少 影响。 本发明治疗高脂血症的方法包括在施用抗血脂药物之前至少2小时预先给予具有缓释NSAID或NSAID和除NSAID和抗脂药物之外的羧酸化合物的患者。 用于增加抗血小板聚集药物的有效性的本发明组合物和试剂盒含有NSAID，例如阿司匹林，烟酸或其同类物，以及任选的除NSAID烟酸之外的羧酸，例如柠檬酸。

    SUBSTITUTED BENZAMIDES AND RADIOLIGAND ANALOGS AND METHODS OF USE
    9.
    发明申请
    SUBSTITUTED BENZAMIDES AND RADIOLIGAND ANALOGS AND METHODS OF USE 审中-公开
    取代的苯甲酸和放射性体模拟物及其使用方法

    公开(公告)号：WO1996017630A1

    公开(公告)日：1996-06-13

    申请号：PCT/US1995015992

    申请日：1995-12-11

    Applicant: VANDERBILT UNIVERSITY ,  DE PAULIS, Tomas ,  SCHMIDT, Dennis, E. ,  HEWLETT, William ,  EBERT, Michael, H.

    Inventor： VANDERBILT UNIVERSITY

    IPC: A61K51/00

    CPC classification number: C07D453/02 ,  A61K51/0455 ,  A61K2123/00

    Abstract: This invention provides compounds of formula (I), wherein R , R , and R are independently a first halogen atom, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, or alkynoxy, wherein R and R can also independently be H, wherein at least one of R , R , and R is a second halogen atom or is substituted with a second halogen atom; R is H or lower alkyl; and R is H or NH2; with the proviso that when R is NH2, R is not H, and when R , R , and R are H, R is not H. The invention also provides precursors of formula (I), radioactive analogs of formula (I), and methods of using the compounds for the identification of 5-HT-3 receptors and the detection and treatment of abnormal conditions associated therewith.

    Abstract translation: 本发明提供式（I）化合物，其中R 1，R 2和R 3独立地是第一个卤素原子，烷基，烯基，炔基，烷氧基，链烯氧基或炔氧基，其中R 2 并且R 3也可以独立地为H，其中R 1，R 2和R 3中的至少一个是第二卤素原子或被第二个卤素原子取代; R 4是H或低级烷基; 且R 5为H或NH 2; 条件是当R 5是NH 2时，R 3不是H，当R 2，R 4和R 5是H时，R 3不是H.本发明 还提供式（I）的前体，式（I）的放射性类似物，以及使用该化合物鉴定5-HT-3受体以及检测和治疗与其相关的异常病症的方法。

Patent Agency Ranking